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Results Nineteen patients were identified with TBC1D24 compound heterozygous mutations.
Nine patients carried the same pathogenic variant c.241_252del. The seizure onset age ranged from 1 day to 8 months of age (median age 75 days). The most prominent features were multifocal myoclonus and epilepsia partialis continua (EPC). The myoclonus could be triggered by fever or infection in 15 patients, and could be terminated by sleep or sedation drugs. Psychomotor developmental delay was presented in 11 patients. Six patients exhibited hearing loss. Brain MRIs were abnormal in eight patients. Twelve patients were diagnosed with epilepsy syndromes including one patient was diagnosed with Dravet syndrome. Two patients died due to status A C C E P T E D M A N U S C R I P T
Introduction
The gene TBC1D24, TBC1 domain family member 24 (OMIM 613577), encodes a protein with an N-terminal Tre2-Bub2-Cdc16 (TBC) domain linked to a TBC-LysM (TLDc) domain [1] . The TBC domain is involved in vesicle trafficking in brain and somatic development, whereas the function of the TLDc domain is largely unknown [1, 2] . In 2010, Falace et al. first mapped the familial infantile myoclonic epilepsy (FIME) locus on chromosome 16p13.3 by linkage analysis. Systematic mutational screening of 34 genes in two affected family members by Sanger sequencing identified two compound heterozygous missense mutations in TBC1D24 [3] . In 2014, Rehman reported that TBC1D24 mutations caused non-syndromic deafness [4] . With the broad application of next generation sequencing (NGS), more diseases associated with TBC1D24 mutations were reported. These diseases included FIME [3] , DOORS (deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures) syndrome [5, 6] , progressive myoclonic epilepsy (PME) [7] , epilepsy of infancy with migrating focal seizures (EIMFS) [8, 9] , early-infantile epileptic encephalopathy-16 (EIEE16) [10] [11] [12] , and autosomal dominant or autosomal recessive
non-syndromic hearing loss [13] [14] [15] [16] . Epilepsia partialis continua (EPC) is clinically defined as a syndrome of continuous focal jerking of a body part, and these symptoms are usually localized to limbs and occur over hours, days or even years [17] . Ragona et al reported that a patient with TBC1D24 compound heterozygous mutations presented with alternating hemiplegia and recurrent episodes of EPC [18] . EPC appears to be common in TBC1D24-related seizure disorders, and all TBC1D24-related types of epilepsies are likely part of the same spectrum. Here, we report 19 epilepsy patients with TBC1D24 mutations and summarize the clinical features.
Materials and Methods
Genetic testing was conducted in all children diagnosed with epilepsy without acquired factors at the Pediatric Neurology Clinic of Peking University First Hospital from March 2015 to July 2018. TBC1D24 mutations were identified using epilepsy NGS panels from March 2015 to June 2017.
The test was conducted as singleton for proband. Segregation analysis was performed by Sanger sequencing with parental DNA samples for all TBC1D24 variants to determine whether the variants were inherited from father/mother or arose de novo. The mutations were identified using trio-based whole exome sequencing (WES) from July 2017 to July 2018 due to the reduction of WES's cost. A customized panel capturing the coding exons of 153 genes associated with epilepsy (Supplementary Table 3 ) was synthesized by Agilent Technologies on a chip (MyGenostics, Baltimore, MD, USA). Targeted gene capture, massive parallel-sequencing, and sequence alignment were performed. For the WES, exon-enriched DNA was sequenced by the Illumina Hiseq2500 platform following the manufacturer's instructions. Synonymous variants and single nucleotide polymorphisms with minor allele frequency (MAF) higher than 5% were removed All epilepsy patients identified with TBC1D24 mutations were followed in outpatient or by telephone. This study was approved by the Ethics Committee of Peking University First Hospital.
Parental written informed consent was obtained for all children included in this study.
Results
A total of 2174 children diagnosed with epilepsy without acquired factors underwent genetic testing using NGS panels of epilepsy or WES, and 19 children were identified with TBC1D24 compound heterozygous mutations. There were 10 males and 9 females, and they were all from nonconsanguineous parents. Abbreviations: NA, not assessed; y, years; m, months; d, days; F, female; M, man; EPC, epilepsia partialis continua; EIMFS, epilepsy of infancy with migrating focal seizures; EIEE, early-infantile epileptic encephalopathy; PME, progressive myoclonic epilepsies; ND, Not done. †, hearing normal before the age of 9 years, then she had bilateral profound sensorineural deafness at 9 years old; ‡, hearing normal after birth, she was found with hearing difficulties after 3 years old, and she was identified with sensorineural deafness at the age of 6 years.
Eighteen TBC1D24 pathogenic variants were identified in 19 patients, and eight were novel variants. The detailed genotypes of 19 patients with TBC1D24 mutations are shown in Table 1 . All variants were assessed by MutationTaster, PolyPhen-2, and SIFT and evaluated according to the ACMG guidelines. All of these variants are pathogenic or likely pathogenic. These data and gnomAD variant frequencies are shown in Supplemental Table 2 . Patient 11 had one variant inherited from his mother, and another variant was de novo. This de novo variant was confirmed to be of paternal origin by allele-specific PCR. The result was shown in Supplementary Figure 1 .
Among the 16 patients, the two variants were inherited from his/her father and mother. Paternal DNA for patients 1 and 12 was not available due to loss of follow-up, and the DNA of other relatives was not available. We only know that one of the two variants was inherited maternally. All of the 19 patients had focal seizures, manifesting as eyes staring to one side, unilateral limbs clonus or body deflecting to one side. Three patients had generalized tonic-clonic seizures (GTCS). Only patient 9 had epileptic spasms. All 19 patients exhibited multifocal myoclonus with retained awareness, which could last for a few hours to two weeks. The multifocal myoclonus could be triggered by fever or infections in 15 patients. All patients had EPC, which could be terminated by sleep or sedation drugs. The EPC could be terminated by chloral hydrate in 11 patients. Two patients developed EPC with unawareness during infection and high fever, and Eleven patients presented psychomotor developmental delay. Four patients (patients 2, 6, 8 and 9) exhibited severe developmental delay. They could not hold up their heads before 18 months, and they could only form simple sounds at last follow-up (19 months to 4 years and 7 months).
Six patients (patients 3, 4, 5, 7, 11 and 12) showed mild developmental delay. They could say simple words or sentences at 5 to 6 years old. Patient 10 developed cerebellar ataxia and walked unsteadily after severe EPC during infection at 9 years old. Seven patients showed normal psychomotor development at the last follow-up. Patient 1 could not hold up his head before the death due to status epilepticus at 4 months old.
Six patients exhibited hearing loss. Four patients were found with sensorineural deafness in the neonatal period. The hearing of patients 10 and 13 was normal after birth, but they were found to have sensorineural deafness at 9 years old and 6 years old, respectively. Thirteen patients had normal hearing. The hearing screen results of 19 patients with TBC1D24 mutations are shown in epileptiform discharges were captured in 13 patients. The interictal EEG of five patients were normal in several records. Focal myoclonic jerks were captured in 11 patients. However, only in patient 6, the corresponding scalp EEG was correlated to generalized polyspike-slow waves. The epileptiform discharges of the remaining 10 patients were not correlated to the myoclonus. The We examined 11 patients' nails on their hands and feet, and the data was shown in Table 1 . Except for patient 9, the other 10 patients' nails were normal.
Patients 1 and 6 died due to status epilepticus at the ages of 4 months and 19 months, respectively. The surviving 17 patients were followed up for 1 year to 3 years and 5 months, and the final follow-up age ranged from 2 years and 1 month to 10 years and 3 months. In our 19 patients, 18 patients had tried two or more antiepileptic drugs (AEDs), and the epilepsy was 
Discussion
TBC1D24 compound heterozygous mutations (c.439G>C and c.1526C>T) were initially reported in a FIME family with seven affected individuals [3] . A wide spectrum of epilepsies, non-syndromic deafness, alternating hemiplegia, and recurrent episodes of EPC caused by TBC1D24 mutations have been reported recently [2, 8, 9, 13] . In this study, we expanded the phenotypic spectrum, and found that Dravet syndrome was also associated with TBC1D24 mutations. The patient was initially diagnosed with Dravet syndrome, but the SCN1A mutation screening was negative. She was identified with TBC1D24 mutations by epilepsy gene panel. Her seizure onset age was 3 months, and her epilepsy was refractory. The seizures included GTCS, focal motor seizures, multifocal myoclonus, and EPC. The prolonged focal or myoclonic seizures were often triggered by fever. She had psychomotor development delay and normal brain MRI.
In our cohort, only patient 9 was diagnosed with DOORS. Patients 1,6 and 8 also exhibited neonatal deafness, developmental delay and frequent seizures. Patients 1 and 6 died due to status epilepticus at 4 months and 19 months of age, respectively. However, these patients did not have their limbs assessed for nail or digit hypoplasia. We suspect that patients 1,6 and 8 may still represent DOORS syndrome.
Although different epilepsy syndromes were related to TBC1D24 mutation, we found that there were some common features of TBC1D24-related epilepsy. In our patient cohorts, the most prominent clinical feature among epilepsy types was multifocal myoclonus. All patients had recurrent EPC, which could be terminated after taking sedative drugs or falling asleep. Ngoh et al
found that the seizures of two patients with TBC1D24 mutation could be abolished after asleep and suggested that the best therapeutic strategy was to use chloral hydrate to induce sleep during prolonged myoclonus [22] . Another common clinical feature of TBC1D24-related epilepsy was fever-induced seizures. Balestrini et al found that seizures were easily exacerbated by fatigue in TBC1D24 mutation-related epilepsy [2] . However, in our study, we found that seizures were exacerbated during fever or infection in 16 patients. In summary, EPC and fever-induced seizures were significant clinical features of TBC1D24-related epilepsy. It is critical to control the infection and temperature to terminate EPC.
No clear correlation between seizure attacks and ictal scalp EEG was another important feature in patients with TBC1D24 mutations [8, 23, 24] . In this study, epileptic discharges were not correlated to focal myoclonus in 10 cases. However, jerk-locked back averaging confirmed that the myoclonus were cortical origin [18, 25] . Several studies have found cerebellar atrophy or cerebellar atrophy with abnormal MRI signals in patients with TBC1D24 mutations [20, 22, [25] [26] [27] . In our study, abnormal brain MRI was found in eight patients, including cerebellar atrophy, cerebral atrophy and abnormal signals in cerebella. Two patients were found to be cerebellar atrophy with abnormal signals after a prolonged myoclonus induced by infection and fever.
Hearing loss was common in TBC1D24 mutation-related epilepsy, and it could occur and exacerbate during follow up.
TBC1D24 mutation-causing epilepsy was mostly drug-resistant [2, 22, 25] . Balestrini [2] has summarized the treatment of 48 patients (11 previously unreported and 37 published) with TBC1D24 mutations. The seizures were controlled in only 18 patients. The most effective antiepileptic drugs were VPA combined with phenobarbital [2] . None of our 19 patients were
seizure free. Seizure frequency was reduced in 14 patients, and the most effective drugs were VPA and clobazam. One patient under a ketogenic diet for 1.5 years showed reduced seizures.
According to the literature, 19% of patients with TBC1D24 gene mutations were deceased before the age of 8 years [2, 27] . The percentage could reach to 32% in DOORS syndrome, and most of them died before the age of 2 years [28] . The cause of death was mainly due to status epilepticus, respiratory distress, and sudden unexpected death (SUDEP) [27, 28] . Two patients in our cohort died from status epilepticus. Most of the patients in our study were still young, and further follow-ups are needed to determine the final outcome.
Eighteen TBC1D24 variants were identified in our 19 patients, of which eight were novel.
Nine patients carried the same pathogenic variant c.241_252del, and this variant has been previously reported in one Chinese epilepsy patient [21] . 
Conclusion
In summary, multifocal myoclonus, EPC, and fever-induced seizures were the most prominent features of epilepsy patients with TBC1D24 mutations. The best therapeutic strategy to terminate EPC might be using chloral hydrate to induce sleep and control the infection and temperature. 
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